117 S3581 IS: Natural Immunity Transparency Act U.S. Senate 2022-02-03 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

II117th CONGRESS2d SessionS. 3581IN THE SENATE OF THE UNITED STATESFebruary 3, 2022Mr. Braun (for himself and Mr. Lankford) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and PensionsA BILLTo direct the Secretary of Health and Human Services to submit to Congress a report on COVID–19 natural immunity, and for other purposes.

1.

Short title

This Act may be cited as the Natural Immunity Transparency Act.

2.

Report on COVID–19 natural immunity

(a)

In general

Not later than 30 days after the date of enactment of this Act, the Secretary of Health and Human Services shall submit to Congress a report that contains—(1)the number of individuals who recovered from a COVID–19 infection, and never received a COVID–19 vaccine, during the period beginning on January 1, 2020, and ending on such date of enactment, and who subsequently—(A)died from a COVID–19 infection;(B)were hospitalized from a COVID–19 infection; (C)had an additional confirmed case of COVID–19; or(D) transmitted SARS–CoV–2 to another person or persons while reinfected; and(2)the number of individuals who received all recommended doses of a COVID–19 vaccine during the period beginning on December 14, 2020, and ending on such date of enactment, and who subsequently—(A)died from a COVID–19 infection;(B)were hospitalized from a COVID–19 infection; or(C)had a confirmed breakthrough case.(b)

Definitions

In this section:(1)

Breakthrough case

The term breakthrough case, with respect to a case of COVID–19, means the detection of SARS–CoV–2 RNA or antigen in a respiratory specimen collected from an individual at least 14 days after the date on which such individual received all recommended doses of a COVID–19 vaccine.(2)

COVID–19 vaccine

The term COVID–19 vaccine means a vaccine for COVID–19 that has been licensed under section 351 of the Public Health Service Act (42 U.S.C. 262) or authorized for emergency use under section 564 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb–3).